Hua Medicine (Shanghai) Ltd. (HKG:2552)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.380
+0.040 (1.20%)
Apr 29, 2026, 4:08 PM HKT
56.48%
Market Cap 3.37B
Revenue (ttm) 548.54M
Net Income (ttm) 1.23B
Shares Out 996.52M
EPS (ttm) 1.22
PE Ratio 2.76
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,709,500
Average Volume 3,376,754
Open 3.370
Previous Close 3.340
Day's Range 3.320 - 3.430
52-Week Range 1.870 - 4.950
Beta 0.89
RSI 45.28
Earnings Date Mar 26, 2026

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic diseas... [Read more]

Sector Healthcare
Founded 2011
Employees 328
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2552
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

Hua Medicine (Shanghai) Earnings Call Transcript: H2 2025

Revenue grew 93% year-over-year with strong sales and improved margins, achieving profitability in commercialization. Patent and NRDL price extensions support future growth, with ambitious revenue targets and international expansion underway.

4 weeks ago - Transcripts

Hua Medicine (Shanghai) Earnings Call Transcript: H1 2025

Revenue more than doubled year-over-year in H1 2025, driven by Dorzagliatin's commercialization and operational efficiency, with gross margin rising to 54%. Confident in reaching RMB 1 billion sales by 2027, supported by global expansion and new product launches.

8 months ago - Transcripts

Hua Medicine (Shanghai) Earnings Call Transcript: H2 2024

Transitioned to full commercialization, ending Bayer partnership and driving dorzagliatin sales growth. Net sales surged nearly 200% early in 2025, with a strong cash position and plans to reach RMB 1 billion sales and break-even by 2027. Expanding into new markets and developing a second-generation GKA.

1 year ago - Transcripts